Amphivena is a company that has been successful for the last ten year. It is a therapeutic company that is based out of San Francisco. Regarding research, it has made groundbreaking discoveries on guenotllc.com. It is an organization that is working to discover ways in which blood cancers can be eliminated from the face of the world. It is led by JeanMarie Guenot who is the President and the Chief Executive Officer of the company.
Perhaps that is the reason why Amphivena has been successful in the field of research. Jeanmarie Guenot’s leadership is unmatched because she is experienced. She has all it takes to work for the firm to the right direction of coming up with ways to combat blood cancer for the restoration of formation of blood and also the circulation. She has accomplished a lot concerning her career. Remember that apart from leading Amphivena to great heights, she also has twenty years of experience in the area of pharmaceutical as well as Biochemistry. Other things that she is experienced in include pharmaceutical R & D, commercial development and many areas of business.
Jeanmarie Guenot is the mastermind behind building and establishment of SKS Ocular. She started the firm even before going to Amphivena. The company is a startup ophthalmic incubator. Reports say that during his tenure with SKS Ocular, she became involved in various areas such as treating of inflammation, macular degeneration, and other issues that are related to medicine. She continued shining in her career and even became the advisor for Hoffmann-La Roche. She has also served as the Vice President of Business Development at PDL BioPharma and Corporate.
JeanMarie Guenot is experienced, and that can be seen from her past accomplishments in the medical field. Apart from being in the medical field, she is also involved in businesses, and that is why she has acquired the leadership skills. She has served many organizations which have praised his hard work and dedication in accomplishing what she wants. Her experience is what has enabled her to lead Amphivena to achieve a lot regarding research and discoveries. They are now working as to come up with first class bi-functional antibody therapy.
Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance